Breakthrough CAR-T cancer treatment provides 100% response rate for multiple myeloma

Success arises from a new cell and gene therapy for multiple myeloma – a blood cancer.

33 out of the 35 patients in a study responded positively and were in some level of remission within two months. In a second study of nearly two-dozen, everyone above a certain dose responded. “I can't say we may get a cure but at least we bring hope of that possibility," said Dr. Frank Fan. 

Read more from the original article on NBC News

PrecisionPlan for Oncology Professionals

Build Actionable, Patient-Specific Cancer Treatment Plans

Integrate or embed our cognitive computing platform into your health system or cancer center EMR to make optimal, personalized, and patient-centered decisions.

Our codified clinical knowledge allows for expert-to-expert consultations and actionable patient-specific pathways built in seconds. 

PrecisionPlan™ is a comprehensive and continuum-based platform that outlines in detail the most appropriate clinical guidance in chemotherapy, immunotherapy, genomic-guided targeted therapy, anti-hormonal therapy, radiation therapy, surgery, supportive care, palliative care and follow up/survivorship that is unique to each patient.

Topics: